CORRESP Filing
Calidi Biotherapeutics, Inc.
Date: Aug. 19, 2025 · CIK: 0001855485 · Accession: 0001641172-25-024762
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289670
Letter
Re: Calidi Biotherapeutics, Inc.
August 19, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F Street NE
Washington, D.C. 20549
Registration Statement on Form S-1
File No. 333-289670
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Calidi Biotherapeutics, Inc. (the "Company") hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it may become effective at 9:00 a.m., Eastern Time, on Wednesday, August 20, 2025, or as soon as practicable thereafter, unless the Company notifies you otherwise prior to such time.
Once the Registration Statement has been declared effective, please confirm orally that event with our counsel, Sichenzia Ross Ference Carmel LLP, by contacting Rohini Sud at (212) 398-9026 or rsud@srfc.law.
Very
truly yours,
/s/
Andrew Jackson
Show Raw Text
CORRESP 1 filename1.htm August 19, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Re: Calidi Biotherapeutics, Inc. Registration Statement on Form S-1 File No. 333-289670 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Calidi Biotherapeutics, Inc. (the "Company") hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it may become effective at 9:00 a.m., Eastern Time, on Wednesday, August 20, 2025, or as soon as practicable thereafter, unless the Company notifies you otherwise prior to such time. Once the Registration Statement has been declared effective, please confirm orally that event with our counsel, Sichenzia Ross Ference Carmel LLP, by contacting Rohini Sud at (212) 398-9026 or rsud@srfc.law. Very truly yours, /s/ Andrew Jackson Andrew Jackson Chief Financial Officer